Acid-suppressive effect of tegoprazan 12.5 mg BID: a phase 1 comparative study with tegoprazan 25 mg QD and famotidine 20 mg BID Authors: Ho-Sook Kim, Young-Kyung Choi, Minkyung Oh, Yong-Soon Cho, Jong-Lyul Ghim Published: 2025 ABSTRACT Tegoprazan is a potassium-competitive acid blocker that directly inhibits the gastric proton pump, whereas famotidine is a histamine-2 receptor antagonist that indirectly suppresses acid secretion with known tolerance to repeated dosing. This phase 1 study evaluated the pharmacokinetics, pharmacodynamics, and safety of tegoprazan 12.5 mg twice daily (BID) compared with tegoprazan 25 mg once daily (QD) and famotidine 20 mg BID in healthy subjects. Thirty-six participants were randomized to one of the 3 regimens for 14 days. In pharmacokinetic analysis, tegoprazan 12.5 mg BID showed lower steady-state Cmax but higher trough concentrations than 25 mg QD, while overall systemic exposure was comparable, with a Day 14 geometric mean ratio for area under the concentration-time curve over 24 hours of 1.08 (90% confidence interval, 0.85–1.36). Pharmacodynamic assessment using 24-hour intragastric pH monitoring demonstrated superior and sustained acid suppression with tegoprazan 12.5 mg BID. On Day 14, the percentage of time with intragastric pH > 3 over 24 hours was 75.1% with tegoprazan 12.5 mg BID, compared with 55.4% with 25 mg QD and 40.3% with famotidine. Both tegoprazan regimens maintained relatively consistent acid suppression from Day 1 to Day 14 (71.8% to 75.1% and 56.4% to 55.4%), whereas famotidine showed a decline (65.3% to 40.3%). Similar time-dependent patterns were observed during the nighttime period and in the supine position. Tegoprazan 12.5 mg BID was well tolerated, with no adverse events reported in this group. These findings suggest that low-dose tegoprazan 12.5 mg BID provides safe and sustained acid suppression. INTRODUCTION Tegoprazan is a potassium-competitive acid blocker developed by HK inno.N to overcome the limitations of traditional proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs), such as delayed onset and inconsistent acid suppression. It provides rapid and sustained inhibition of gastric acid secretion. Tegoprazan 50 mg (K-CAB®) has been approved for the treatment of erosive and non-erosive gastroesophageal reflux disease (GERD), gastric ulcers, and as part of combination therapy for Helicobacter pylori eradication in patients with peptic ulcers or chronic atrophic gastritis [1234]. A lower-dose formulation, tegoprazan 25 mg, was recently approved for maintenance therapy following treatment of erosive GERD and has demonstrated both safety and efficacy for up to 6 months of continuous use [5]. Acid-suppressive agents play an essential role not only in the treatment of acid-related gastrointestinal diseases but also in the prevention of upper gastrointestinal symptoms induced by medications such as nonsteroidal anti-inflammatory drugs (NSAIDs) and antiplatelet agents. With an aging population and the increasing prevalence of chronic conditions such as cardiovascular and musculoskeletal diseases, the use of NSAIDs and aspirin has risen. Given their associated risk of gastrointestinal injury, co-prescription of acid-suppressive agents is strongly recommended [6]. In such preventive strategies, PPIs are often prescribed at submaximal doses based on their dose-dependent acid-inhibitory effects. H2RAs, while less potent than PPIs in acid suppression, are widely used for intermittent or mild GERD, peptic ulcers, and gastritis due to their rapid onset, twice-daily dosing for prolonged effect, and cost-effectiveness. H2RAs are particularly effective in suppressing nocturnal acid secretion, largely owing to their twice-daily regimen. Standard once-daily PPI therapy in the morning often fails to adequately control nighttime acid breakthrough, and the addition of an H2RA at bedtime has been shown to improve nocturnal acid suppression [78]. A meta-analysis of 8 randomized controlled trials demonstrated a reduction in the frequency of nocturnal acid breakthrough when a bedtime H2RA was added [9]. However, H2RAs are limited by the rapid development of tolerance with long-term use. For example, the acid-inhibitory effect of famotidine was shown to decrease after just 7 days of treatment [10]. In contrast, a previous study demonstrated that tegoprazan maintained its acid-suppressive effect over a 7-day period [11]. These findings suggest the potential value of low-dose tegoprazan regimens in the treatment or prevention of acid-related upper gastrointestinal symptoms, by overcoming the limitations of conventional PPIs and H2RAs while maintaining efficacy. Identifying the optimal dose and dosing schedule could enable effective symptom control with minimal adverse effects. Therefore, in this phase 1 clinical trial, we aimed to evaluate the pharmacokinetics (PKs), pharmacodynamics (PDs), and safety of tegoprazan 12.5 mg administered twice daily (BID) compared with tegoprazan 25 mg once daily (QD) and famotidine 20 mg BID in healthy subjects. We further explored whether this dose could represent a minimally effective dose by comparing its acid-suppressive effects with those of tegoprazan 25 mg QD and famotidine 20 mg BID, with a particular focus on nocturnal acid suppression. METHODS Subjects This study was reviewed and approved by the Institutional Review Board (IRB) of Inje University Busan Paik Hospital (IRB No. 2024-11-005) and authorized by the Korean Ministry of Food and Drug Safety. The trial adhered to the principles outlined in the Declaration of Helsinki and complied with the International Council for Harmonisation Good Clinical Practice guidelines. All volunteers were given a detailed explanation of the study procedures, potential risks, and expected benefits prior to participation, and written informed consent was obtained from each subject before any study-related activity. Healthy volunteers between 19 and 45 years of age, with a body mass index (BMI) ranging from 18.5 to 28.0 kg/m2, were considered eligible for inclusion. Key exclusion criteria included a medical history or clinical evidence of dysfunction involving hepatic, renal, gastrointestinal, pulmonary, musculoskeletal, endocrine, psychiatric, hematologic-oncologic, urologic, or cardiovascular systems. Individuals with any condition that would interfere with pH catheter insertion, clinically significant abnormalities on baseline electrocardiogram (ECG), or laboratory findings exceeding the normal range were excluded. Specifically, subjects with alanine aminotransferase or aspartate aminotransferase levels > 1.5× the upper limit of normal (ULN), or total bilirubin > 2× ULN, were not eligible. Subjects who tested positive for H. pylori were also excluded, as chronic H. pylori infection may alter basal and stimulated gastric acid secretion and thereby confound the PD assessment. Additional exclusion criteria included a positive result in a drug screening test, history of hypersensitivity to drugs, current or past substance abuse, use of medications known to influence the PKs of the investigational drug, intake of any medication within 10 days before screening, enrollment in another clinical trial within the past 6 months, or whole blood donation within 60 days prior to screening. Subjects were also excluded if they failed to comply with medically acceptable contraception requirements, reported alcohol intake exceeding 30 g/day, smoked more than 10 cigarettes/day, or consumed over 400 mg/day of caffeine. Study design This was a randomized, open-label, multiple-dose, active-controlled, parallel-group study. A total of 36 healthy adult subjects were randomly assigned in a 1:1:1 ratio to one of the following 3 treatment groups: Group A (tegoprazan 12.5 mg BID), Group B (tegoprazan 25 mg QD), or Group C (famotidine 20 mg BID). All study medications were administered with 150 mL of water for 14 consecutive days, 30 minutes after the start of a standardized meal. As the morning and evening standardized meals were scheduled 12 hours apart, the twice-daily doses in Groups A and C were also administered 12 hours apart. Due to equipment limitations, subjects were admitted in 4 separate batches of 9 participants each. All participants were hospitalized for 16 nights and 17 days and completed a follow-up visit after discharge. PK evaluation PK blood samples were collected on Days 1 and 14 at multiple time points to characterize the concentration–time profile of tegoprazan and active metabolite M1. In Group A (12.5 mg BID), samples were obtained at 0 (pre-dose), 0.33, 0.66, 1, 1.5, 2, 3, 4, 8, 12, 12.33, 12.66, 13, 13.5, 14, 15, 16, 20, and 24 hours after the morning dose on Day 1, and at −12 and 0 (pre-dose), 0.33, 0.66, 1, 1.5, 2, 3, 4, 8, 12, 12.33, 12.66, 13, 13.5, 14, 15, 16, 20, and 24 hours on Day 14, capturing both dosing intervals. In Group B (25 mg QD), samples were collected at 0 (pre-dose), 0.33, 0.66, 1, 1.5, 2, 3, 4, 8, 12, 16, and 24 hours on Day 1, and at −12 and 0 (pre-dose), 0.33, 0.66, 1, 1.5, 2, 3, 4, 8, 12, 16, and 24 hours on Day 14. PK parameters were derived using non-compartmental methods implemented in Phoenix WinNonlin version 8.3 (Certara, Princeton, NJ, USA). On Day 1 Parameters included the maximum observed plasma concentration (Cmax), time to reach Cmax (Tmax), area under the plasma concentration–time curve over 24 hours (AUC0-24). For the 12.5 mg BID regimen, AUC0–24 was calculated as the sum of the AUCs following the morning and evening doses. For Cmax comparisons, the higher value between the morning and evening Cmax was used as the representative Cmax. On Day 14, PK parameters included maximum and minimum plasma concentrations at steady-state (Cmax,ss and Cmin,ss), average plasma concentration at steady-state (Cavg,ss, calculated as AUC0-24 on Day 14 divided by 24 hours). Terminal elimination half-life (t1/2β on Day 1 and t1/2β,ss on Day 14) was calculated as ln(2)/λz, where λz is the terminal elimination rate constant estimated by linear regression of the log-linear terminal phase following the morning dose in BID regimen. When λz was based on fewer than 3 data points, the half-life was not estimated and reported as “Not Estimated.” Observed accumulation index was calculated as the ratio of AUC0-24 on Day 14 to that on Day 1, and fluctuation was computed as (Cmax,ss − Cmin,ss)/Cavg,ss. Predicted accumulation index was derived from λz using 1/(1 − e−λz·τ), with τ representing the dosing interval. Bioanalysis At each scheduled PK sampling point, 7 mL of venous blood was collected into EDTA K2 tubes using an intravenous catheter or syringe. The samples were stored in an ice bath immediately after collection and centrifuged within 30 minutes at 2,000 g for 10 minutes at 4°C. Plasma (0.5 mL) was aliquoted into cryovials and stored at −80°C until analysis. Plasma concentrations of tegoprazan and active metabolite, M1 were quantified using a validated liquid chromatography-tandem mass spectrometry method [12]. The bioanalysis was conducted by the bioanalytical team at BioInfra (Suwon, Korea). The precision and accuracy of the analytical method were confirmed based on the analysis of calibration standards and QC samples at 2.00, 6.00, 600, and 1,500 ng/mL, with all within-run and between-run relative standard deviation (SD) values ≤ 14.2% and percentage deviation of the mean from the theoretical concentration values within ± 13.5%, meeting the acceptance criteria of ≤ 15.0% (≤ 20.0% for lower limits of quantification). PD evaluation PD evaluation was performed using 24-hour intragastric pH monitoring with an ambulatory pH monitoring system (Digitrapper™ pH-Z, Medtronic, Minneapolis, MN, USA). The system was calibrated prior to use using standard pH 4.0 and 7.0 buffer solutions in accordance with the manufacturer’s instructions and clinical practice guidelines [13]. A pH-sensitive catheter was transnasally inserted into the stomach, and pH recording was initiated simultaneously with the ingestion of 150 mL of water at the scheduled dosing time. pH monitoring was conducted on Day −1 (baseline), and Days 1, 7, and 14. On each monitoring day, subjects remained in a seated position for 2 hours following drug administration, after which routine non-strenuous activities were permitted. Subjects maintained an upright posture (sitting or standing) at all times except during the designated supine period from 23:00 to 07:00. Daytime and nighttime were defined as 0–12 hours (08:00 to 20:00) and 12–24 hours (20:00 to 08:00), respectively. To standardize physiological conditions, all participants remained fasting for 4 hours after drug administration on pH monitoring days; water was permitted after 2 hours. The same pre-dose water ingestion was replicated on Day −1 to mimic study drug administration conditions. PD parameters included the mean and median intragastric pH over the 24-hour monitoring period; the percentage of time with pH above 3 (TpH > 3) and above 4 (TpH > 4); and the changes in these parameters from baseline (Δ mean pH, Δ median pH, Δ TpH > 3, and Δ TpH > 4). Additional analyses were performed for daytime (08:00–20:00) and nighttime (20:00–08:00) intervals, as well as upright (08:00–23:00, 07:00–08:00) and supine (23:00–07:00) positions. Safety evaluation Safety was assessed throughout the study through adverse event (AE) monitoring, physical examinations, clinical laboratory tests, vital signs, and 12-lead ECGs conducted at scheduled intervals. All clinically relevant abnormalities were recorded as AEs. Each event was evaluated by the investigators for severity, seriousness, outcome, and its possible relationship to the study drug. AEs were coded by System Organ Class and Preferred Term, and their frequency and incidence were summarized by treatment group and severity. Drug-related AEs leading to discontinuation were specifically listed. Descriptive statistics were used to summarize changes in laboratory values, ECG findings, physical examination and vital signs from baseline across time points. Statistical considerations This study was exploratory in nature and was not based on formal power calculations. However, reference to prior studies suggested that a sample size of 10 subjects per group would be sufficient to detect a meaningful difference in the percentage of time with intragastric pH > 4 (TpH > 4) between treatment arms. For example, after repeated administration for 7 days, tegoprazan 25 mg QD and famotidine 20 mg BID were previously reported to yield mean TpH > 4 values of 56.6% (SD, 17.9) and 36.2% (SD, 8.7), respectively [10], corresponding to an estimated power of 85.3% at a 2-sided significance level of 0.05. Considering the exploratory objectives of the study and allowing for potential dropouts, a total of 36 participants (12 per treatment group) were planned for enrollment. The PK parameters Cmax and AUC0-24 were log-transformed and compared between treatment groups using analysis of variance (ANOVA) at a significance level of 0.05. A mixed-effects model was used, with treatment and separate hospitalization group (4 separate admission batches of 9 participants each) as fixed effects and subject as a random effect. Geometric mean ratios (GMRs) and their 90% confidence intervals were derived from this model as the ratio of the 12.5 mg BID group to the 25 mg QD group, with Group B serving as the reference. To assess steady-state attainment, trough (pre-dose) plasma concentrations at 12 hours on Day 13 and at 0, 12, and 24 hours on Day 14 in the BID group, and at 0 and 24 hours on Day 14 in the QD group, were analysed using a linear mixed-effects model with time as a fixed effect and subject as a random effect. For PD analysis, differences in PD parameters between treatment groups (A vs. B, A vs. C, and B vs. C) were tested using either independent 2-sample t-tests or Mann–Whitney U tests, depending on data normality. Within-group comparisons across time points (Day 1 vs. Day 7, Day 1 vs. Day 14, and Day 7 vs. Day 14) were evaluated using paired t-tests or Wilcoxon signed-rank tests. To control for Type I error due to multiple comparisons, Bonferroni correction was applied, with statistical significance set at α = 0.0167. RESULTS Subjects All 36 participants who received at least one dose of the investigational product were male and were included in the safety analysis set. Among them, 24 subjects who completed all scheduled PK blood samplings per protocol were included in the PK analysis set. The PD analysis set comprised 34 subjects, excluding 2 individuals—one with improper pH catheter placement and another who did not complete the PD assessments. No participants had prior or concomitant medications that were expected to affect PK or PD outcomes. The mean age was 26.8 ± 5.4 years in the 12.5 mg BID group, 28.9 ± 5.4 years in the 25 mg QD group, and 25.5 ± 2.9 years in the famotidine group. The corresponding mean body weights were 66.5 ± 9.1 kg, 71.0 ± 10.9 kg, and 68.0 ± 7.4 kg, respectively. The mean heights were 173.4 ± 6.0 cm, 173.4 ± 6.0 cm, and 172.1 ± 4.1 cm, and the mean BMI values were 22.0 ± 2.6 kg/m2, 23.5 ± 2.8 kg/m2, and 22.9 ± 2.2 kg/m2, respectively, indicating comparable baseline demographic characteristics across the 3 treatment groups. PKs Steady-state attainment was confirmed in both treatment groups based on repeated trough concentration analysis. In the 12.5 mg twice-daily group, trough concentrations at 12 hours on Day 13 and at 0, 12, and 24 hours on Day 14 showed no significant differences over time based on a linear mixed-effects model, indicating achievement of steady state (p = 0.112). Similarly, in the 25 mg QD group, trough concentrations measured at 0 and 24 hours on Day 14 were comparable, confirming steady-state conditions (p = 0.956). On Day 14, the mean trough concentrations in the 12.5 mg BID group were notably higher than those in the 25 mg QD group (50.87 vs. 11.79 ng/mL at 0 hour and 51.37 vs. 11.74 ng/mL at 24 hours). The mean plasma concentration–time profiles of tegoprazan and its active metabolite M1 are shown in Fig. 1, and the corresponding PK parameters are summarized in Table 1. Following single administration of tegoprazan 12.5 mg, Cmax was reached at a median of 3.00 hours with a mean concentration of 99.98 ng/mL and eliminated with a mean t1/2β of 4.05 hours. After 14 days of repeated dosing, the morning dose yielded a Cmax of 120.68 ng/mL (median Tmax 4.00 hours) with a mean t1/2β of 4.52 hours. For the evening doses, Cmax was 88.19 ng/mL (median Tmax 2.99 hours, t1/2β 5.69 hours) on Day 1 and 108.68 ng/mL (median Tmax 3.50 hours, t1/2β 6.71 hours) on Day 14, showing comparable trends to those observed for the morning doses. Mean plasma concentration—time profiles of tegoprazan (A) and its active metabolite M1 (B) following 14-day oral administration of tegoprazan 12.5 mg BID or 25 mg QD in healthy subjects. Data are expressed as mean ± standard deviation. BID, twice daily; QD, once daily; PO, per os. Table 1Pharmacokinetic parameters of tegoprazan and its active metabolite M1 following single (Day 1) and multiple (Day 14) oral doses of tegoprazan 12.5 mg twice daily or 25 mg once dailyParametersTegoprazanM112.5 mg BID25 mg QD12.5 mg BID25 mg QDDay 1 (n = 12)Day 14 (n = 12)Day 1 (n = 12)Day 14 (n = 12)Day 1 (n = 12)Day 14 (n = 12)Day 1 (n = 12)Day 14 (n = 12)Cmax (ng/mL)99.98 ± 24.77120.68 ± 30.47151.33 ± 27.2189.33 ± 47.9625.93 ± 3.270.71 ± 15.8943.98 ± 9.5872.82 ± 24.45Cmin,ss (ng/mL)-39.3 ± 21.66-10.67 ± 7.02-47.63 ± 13.32-27.48 ± 8.55AUC0–24 (ng*h/mL)1,185.59 ± 378.41,672.82 ± 599.931,221.01 ± 316.731,506.86 ± 377.51609.84 ± 107.541,374.3 ± 311.34729.79 ± 149.221,184.3 ± 322.62Tmax (h)3 (0.66–8)4 (1.5–11.98)3 (1–4)3 (1.5–8)11.97 (4–11.98)4 (0–11.97)11.97 (8–11.97)10.03 (4–12)t1/2 β (h)4.05 ± 0.934.52 ± 2.064.71 ± 1.085 ± 0.92NENE12.59 ± 2.5914.8 ± 4.06Values are presented as mean ± standard deviation or median (range).BID, twice daily; QD, once daily; Cmax, maximum plasma concentration; Cmin,ss, minimum plasma concentration at steady state; AUC0-24, area under the plasma concentration–time curve over 24 hours; Tmax, time to reach Cmax; t½β, terminal elimination half-life after the morning dose; NE, not estimated. Pharmacokinetic parameters of tegoprazan and its active metabolite M1 following single (Day 1) and multiple (Day 14) oral doses of tegoprazan 12.5 mg twice daily or 25 mg once daily Values are presented as mean ± standard deviation or median (range). BID, twice daily; QD, once daily; Cmax, maximum plasma concentration; Cmin,ss, minimum plasma concentration at steady state; AUC0-24, area under the plasma concentration–time curve over 24 hours; Tmax, time to reach Cmax; t½β, terminal elimination half-life after the morning dose; NE, not estimated. For the 25 mg once-daily group, Cmax values after single and multiple dosing were 151.33 and 189.33 ng/mL, respectively, both with a median Tmax of 3.00 hours and t1/2β values of 4.71 and 5.00 hours, respectively. The GMRs for AUC indicated comparable overall systemic exposure between the 12.5 mg BID and 25 mg QD regimens on both Day 1 and Day 14. In contrast, the Cmax values with the 12.5 mg BID regimen were consistently higher than half of those observed with the 25 mg QD regimen (Table 2). Table 2Geometric mean ratios and 90% CIs for pharmacokinetic parameters of tegoprazan (12.5 mg BID vs. 25 mg QD)ParametersDayGMR (12.5 mg BID/25 mg QD)90% CICmax Day 10.680.58–0.79Day 140.670.57–0.80AUC0–24 Day 10.960.77–1.19Day 141.080.85–1.36CI, confidence interval; BID, twice daily; QD, once daily; GMR, geometric mean ratio; Cmax, maximum plasma concentration; AUC0-24, area under the concentration–time curve over 24 hours.AUC0-24 were obtained from a mixed-effects model with treatment and hospitalization batch as fixed effects and subject as a random effect. AUC values represent 24-hour exposure for both regimens. Geometric mean ratios and 90% CIs for pharmacokinetic parameters of tegoprazan (12.5 mg BID vs. 25 mg QD) CI, confidence interval; BID, twice daily; QD, once daily; GMR, geometric mean ratio; Cmax, maximum plasma concentration; AUC0-24, area under the concentration–time curve over 24 hours. AUC0-24 were obtained from a mixed-effects model with treatment and hospitalization batch as fixed effects and subject as a random effect. AUC values represent 24-hour exposure for both regimens. Although the per-dose amount of 12.5 mg BID is half that of 25 mg QD, the observed Cmax,ss values were approximately 67% of those in the QD group. This exceeds the expected 0.5 ratio based solely on dose, reflecting the influence of dosing frequency and drug accumulation. Because Cmax,ss is affected not only by dose but also by the dosing interval relative to the drug's half-life, a strictly proportional relationship should not be expected. Observed accumulation indices were 1.40 for the 12.5 mg group and 1.24 for the 25 mg group. These exceeded the predicted indices of 1.00 and 1.03, respectively, but remained within the range defined as weak accumulation (1.2 ≤ AI < 2) and thus were not considered to indicate meaningful dose- and time-dependency [14]. The active metabolite M1 reached Cmax at a median of 11.97 hours (mean 25.93 ng/mL) and 9.93 hours (49.38 ng/mL) after the morning and evening doses of 12.5 mg on Day 1, respectively. After repeated dosing, Cmax increased to 70.71 ng/mL and 73.31 ng/mL, observed at 4.00 hours and 8.00 hours, respectively. For the 25 mg group, M1 reached Cmax at 11.97 hours (43.98 ng/mL) and 10.03 hours (72.82 ng/mL) after single and multiple dosing, with corresponding elimination half-lives of 12.59 hours and 14.80 hours [15]. PDs PD parameters over 24 hours (0–24 hours), nighttime (20:00–08:00), and supine position (23:00–07:00) are summarized in Table 3, and the corresponding baseline-adjusted values are presented in Table 4. Table 3Unadjusted pharmacodynamic parameters of intragastric pH following repeated doses of tegoprazan or famotidine in healthy subjectsTime periodParametersDay −1Day 1Day 7Day 14A (n = 12)B (n = 10)C (n = 12)A (n = 12)B (n = 10)C (n = 12)A (n = 12)B (n = 10)C (n = 12)A (n = 12)B (n = 10)C (n = 12)Over the 24-h periodMean pH2.78 ± 0.592.53 ± 0.382.62 ± 0.544.34 ± 0.843.91 ± 0.644.15 ± 0.734.57 ± 0.814.02 ± 0.813.29 ± 0.554.53 ± 0.793.8 ± 0.783.04 ± 0.56Median pH2.48 ± 0.661.99 ± 0.372.16 ± 0.614.44 ± 1.133.72 ± 1.183.96 ± 14.78 ± 1.174.05 ± 1.422.93 ± 0.794.76 ± 1.133.53 ± 1.282.65 ± 0.77TpH > 3 (%)33.94 ± 19.1126.44 ± 12.3429.23 ± 14.1671.81 ± 20.2756.44 ± 13.8565.26 ± 15.4373.36 ± 17.5261.82 ± 17.0245.09 ± 14.6475.11 ± 15.5655.38 ± 18.7940.29 ± 13.62TpH > 4 (%)20.67 ± 15.7916.33 ± 9.817.23 ± 13.4457.72 ± 22.3545.91 ± 17.5949.06 ± 18.8563.67 ± 20.5651.41 ± 18.5531.44 ± 14.8564.32 ± 18.0543.86 ± 19.1124.6 ± 14.07Supine positionMean pH2.18 ± 0.641.73 ± 0.091.98 ± 0.523.88 ± 0.862.46 ± 0.384.38 ± 0.984.01 ± 0.83.04 ± 0.883.48 ± 0.794.04 ± 0.82.81 ± 0.762.91 ± 0.74Median pH1.91 ± 0.451.7 ± 0.081.76 ± 0.223.56 ± 1.252.13 ± 0.24.13 ± 1.693.82 ± 1.422.54 ± 0.783.12 ± 1.493.95 ± 1.12.53 ± 0.892.33 ± 0.66TpH > 3 (%)12.88 ± 18.240.24 ± 0.517.08 ± 11.8658.22 ± 25.215.84 ± 11.1759.9 ± 17.9157.58 ± 20.932.75 ± 21.1940.69 ± 19.6664.87 ± 19.2525.34 ± 21.4129.02 ± 19.31TpH > 4 (%)9.84 ± 15.10.1 ± 0.254.61 ± 8.9844.12 ± 25.088.59 ± 9.249.78 ± 21.745.53 ± 19.124.33 ± 19.535.23 ± 17.8249.31 ± 20.6915.97 ± 15.4522.12 ± 16.17Night timeMean pH2.62 ± 0.672.21 ± 0.32.42 ± 0.564.17 ± 0.853.19 ± 0.514.29 ± 0.834.32 ± 0.753.53 ± 0.813.44 ± 0.724.39 ± 0.783.26 ± 0.763.05 ± 0.72Median pH2.18 ± 0.781.76 ± 0.11.93 ± 0.384.18 ± 1.282.4 ± 0.524.02 ± 1.164.44 ± 1.333.29 ± 1.313.08 ± 1.114.59 ± 1.052.8 ± 1.062.58 ± 0.79TpH > 3 (%)26.28 ± 20.1615.51 ± 8.2121.14 ± 13.5366.25 ± 23.1235.21 ± 11.4964.58 ± 14.7566.22 ± 17.5347.19 ± 17.4243.14 ± 18.5572.57 ± 17.0340.46 ± 20.5436.32 ± 18.4TpH > 4 (%)18.09 ± 17.810.28 ± 8.2713.38 ± 12.6452.11 ± 23.2327.04 ± 13.6349.48 ± 19.6354.76 ± 18.0436.87 ± 18.3433.69 ± 17.4459.6 ± 18.2930.11 ± 17.6524.31 ± 16.55Values are presented as mean ± standard deviation.A: tegoprazan 12.5 mg BID; B: tegoprazan 25 mg QD; C: famotidine 20 mg BID; Day −1: baseline (prior to first dosing); Mean pH: arithmetic mean of continuously measured intragastric pH over the specified period; Median pH: median of intragastric pH values over the period; TpH > 3 or > 4: proportion of time during each period in which intragastric pH exceeded 3 or 4, respectively; Over the 24-hour period: 08:00–08:00 the next day; Nighttime: 20:00–08:00; Supine position: 23:00–07:00.BID, twice daily; QD, once daily. Unadjusted pharmacodynamic parameters of intragastric pH following repeated doses of tegoprazan or famotidine in healthy subjects Values are presented as mean ± standard deviation. A: tegoprazan 12.5 mg BID; B: tegoprazan 25 mg QD; C: famotidine 20 mg BID; Day −1: baseline (prior to first dosing); Mean pH: arithmetic mean of continuously measured intragastric pH over the specified period; Median pH: median of intragastric pH values over the period; TpH > 3 or > 4: proportion of time during each period in which intragastric pH exceeded 3 or 4, respectively; Over the 24-hour period: 08:00–08:00 the next day; Nighttime: 20:00–08:00; Supine position: 23:00–07:00. BID, twice daily; QD, once daily. Table 4Baseline-adjusted pharmacodynamic parameters of intragastric ph following repeated doses of tegoprazan or famotidine in healthy subjectsTime periodParametersDay 1Day 7Day 14A (n = 12)B (n = 10)C (n = 12)A (n = 12)B (n = 10)C (n = 12)A (n = 12)B (n = 10)C (n = 12)Over the 24-h periodΔMean pH1.56 ± 0.611.38 ± 0.471.54 ± 0.41.79 ± 0.631.5 ± 0.640.67 ± 0.341.75 ± 0.571.27 ± 0.730.42 ± 0.36ΔMedian pH1.95 ± 0.861.73 ± 1.041.8 ± 0.652.3 ± 0.972.06 ± 1.250.78 ± 0.482.27 ± 1.021.54 ± 1.170.5 ± 0.5ΔTpH >3 (%)37.86 ± 18.7330 ± 8.0236.04 ± 8.3539.42 ± 18.3935.38 ± 12.0415.86 ± 7.5741.17 ± 13.2828.94 ± 16.7311.06 ± 9.59ΔTpH >4 (%)37.06 ± 18.0829.58 ± 13.7531.83 ± 11.8643 ± 16.9135.08 ± 14.6814.21 ± 8.4143.65 ± 14.1627.53 ± 16.977.38 ± 8.98Supine positionΔMean pH1.7 ± 0.830.73 ± 0.352.4 ± 0.631.82 ± 0.881.31 ± 0.881.5 ± 0.771.85 ± 0.621.08 ± 0.740.93 ± 0.66ΔMedian pH1.64 ± 1.090.42 ± 0.172.37 ± 1.591.91 ± 1.390.83 ± 0.761.36 ± 1.472.03 ± 0.960.83 ± 0.880.57 ± 0.64ΔTpH >3 (%)45.34 ± 28.7115.6 ± 10.9652.82 ± 14.1144.7 ± 25.0932.51 ± 21.0333.62 ± 19.551.99 ± 18.2925.1 ± 21.3721.95 ± 18.25ΔTpH >4 (%)34.28 ± 27.078.49 ± 9.1245.16 ± 16.8435.69 ± 20.3524.23 ± 19.4530.61 ± 16.8139.47 ± 15.1215.86 ± 15.4717.51 ± 13.95Night timeΔMean pH1.55 ± 0.670.98 ± 0.411.87 ± 0.471.7 ± 0.721.32 ± 0.771.02 ± 0.571.77 ± 0.531.05 ± 0.710.63 ± 0.52ΔMedian pH2 ± 1.050.64 ± 0.482.09 ± 0.942.26 ± 1.241.53 ± 1.311.16 ± 0.92.41 ± 0.841.04 ± 1.050.65 ± 0.56ΔTpH >3 (%)39.96 ± 23.7919.7 ± 7.1643.43 ± 9.2139.94 ± 21.2931.68 ± 16.8321.99 ± 15.2546.29 ± 17.0524.95 ± 19.9415.18 ± 13.69ΔTpH >4 (%)34.02 ± 22.416.76 ± 11.0936.1 ± 12.9936.67 ± 17.8126.59 ± 17.7620.32 ± 12.3641.52 ± 13.6519.82 ± 16.3410.94 ± 10.18Values are presented as mean ± standard deviation.A: tegoprazan 12.5 mg BID; B: tegoprazan 25 mg QD; C: famotidine 20 mg BID; Day −1: baseline (prior to first dosing); ΔMean pH: change in arithmetic mean of continuously measured intragastric pH from baseline; ΔMedian pH: change in median intragastric pH from baseline; ΔTpH > 3 or > 4: change in the percentage of time with intragastric pH above 3 or 4, respectively, from baseline; Over the 24-hour period: 08:00–08:00 the next day; Nighttime: 20:00–08:00; Supine position: 23:00–07:00.BID, twice daily; QD, once daily. Baseline-adjusted pharmacodynamic parameters of intragastric ph following repeated doses of tegoprazan or famotidine in healthy subjects Values are presented as mean ± standard deviation. A: tegoprazan 12.5 mg BID; B: tegoprazan 25 mg QD; C: famotidine 20 mg BID; Day −1: baseline (prior to first dosing); ΔMean pH: change in arithmetic mean of continuously measured intragastric pH from baseline; ΔMedian pH: change in median intragastric pH from baseline; ΔTpH > 3 or > 4: change in the percentage of time with intragastric pH above 3 or 4, respectively, from baseline; Over the 24-hour period: 08:00–08:00 the next day; Nighttime: 20:00–08:00; Supine position: 23:00–07:00. BID, twice daily; QD, once daily. Mean intragastric pH–time profiles after repeated dosing are shown in Fig. 2, demonstrating the temporal evolution of acid suppression across treatment groups. Fig. 3 presents the mean (± SD) percentage of time with intragastric pH > 3 by treatment group, posture, and study day. Mean 24-hour intragastric pH–time profiles following repeated oral administration of tegoprazan 12.5 mg BID, 25 mg QD, or famotidine 20 mg BID on Day −1 (baseline, A), Day 1 (B), Day 7 (C), and Day 14 (D) in healthy subjects. Data represent mean distal intragastric pH values over time. Meals and scheduled water intake are marked with green and blue arrows, respectively. The shaded area indicates the nighttime (23:00–07:00). BID, twice daily; QD, once daily; PO, per os. Comparative analysis of the percentage of time with intragastric pH > 3 (A-C) and Δpercentage of time with pH > 3 from baseline (D-F) over the 24-hour period following 14-day oral administration of tegoprazan 12.5 mg BID, 25 mg QD, or famotidine 20 mg BID in healthy subjects. Panels (A, D) show comparisons between tegoprazan 12.5 mg BID and 25 mg QD; (B, E) between tegoprazan 25 mg QD and famotidine 20 mg BID; and (C, F) between tegoprazan 12.5 mg BID and famotidine 20 mg BID. Data are presented as mean ± standard deviation. Statistical comparisons were performed using independent 2-sample t-tests or Mann–Whitney U tests. BID, twice daily; QD, once daily; PO, per os. *p < 0.0167 after Bonferroni correction; †Not significant. Over the 24-hour period on Day 14, the mean intragastric pH was 4.53 ± 0.79 in Group A, 3.80 ± 0.78 in Group B, and 3.04 ± 0.56 in Group C. The corresponding TpH > 4 values were 64.32 ± 18.05%, 43.86 ± 19.11%, and 24.60 ± 14.07%, respectively, while TpH > 3 values were 75.11 ± 15.56%, 55.38 ± 18.79%, and 40.29 ± 13.62%, respectively. In pairwise comparisons over 24 hours, no statistically significant differences were observed between Groups A and B for mean pH, median pH, TpH >3, or TpH >4 at any time point. In contrast, comparisons between Groups B and C showed significant differences at Day 7 for TpH >4 (p = 0.0109) and at Day 14 for both mean pH (p = 0.0149) and TpH >4 (p = 0.0132). More pronounced differences were observed between Groups A and C, with mean pH, median pH, TpH >3, and TpH >4 all significantly different at both Day 7 and Day 14 (all p ≤ 0.0004). Baseline-adjusted analyses showed consistent findings. At Day 14, Δmean pH was 1.75 ± 0.57 in Group A, 1.27 ± 0.73 in Group B, and 0.42 ± 0.36 in Group C, with corresponding ΔTpH > 4 values of 43.65 ± 14.16%, 27.53 ± 16.97%, and 7.38 ± 8.98%. Baseline-adjusted ΔTpH > 3 and ΔTpH > 4 differed significantly between Groups B and C and between Groups A and C at both Day 7 and Day 14 (all p ≤ 0.0051), whereas no significant differences were observed between Groups A and B at any time point. These findings demonstrate that acid suppression with famotidine declined significantly over time, while both tegoprazan regimens maintained stable efficacy from Day 7 to Day 14. During the nighttime period, at Day 14, Group A maintained a higher mean pH (4.39 ± 0.78) and greater TpH > 4 (59.60 ± 18.29%) than Group B (3.26 ± 0.76 and 30.11 ± 17.65%) and Group C (3.05 ± 0.72 and 24.31 ± 16.55%). Baseline-adjusted nighttime ΔTpH > 4 at Day 14 was 41.52 ± 13.65% in Group A, compared with 19.82 ± 16.34% in Group B and 10.94 ± 10.18% in Group C. Pairwise testing confirmed that Group A differed significantly from Group C for nighttime mean pH, TpH > 3, and TpH > 4 at both Day 7 and Day 14 (all p ≤ 0.0083), and significant differences between Groups A and B were also observed for multiple nighttime parameters at Day 14 (p ≤ 0.0141). In the supine position, at Day 14, mean pH was 4.04 ± 0.80 in Group A versus 2.81 ± 0.76 in Group B and 2.91 ± 0.74 in Group C. Baseline-adjusted ΔTpH > 4 values were 39.47 ± 15.12%, 15.86 ± 15.47%, and 17.51 ± 13.95%, respectively. Pairwise comparisons showed that Group A was significantly superior to Group C for all key PD parameters (mean pH, TpH > 3, TpH > 4, Δmean pH, ΔTpH > 3, and ΔTpH > 4) at Day 14 in the supine position (all p ≤ 0.0018). Differences between Groups A and B were also significant for several supine parameters at Day 14 (p ≤ 0.0148). Taken together, the superiority of tegoprazan over famotidine—across TpH > 3 and TpH > 4, baseline-adjusted parameters, postural conditions, and nighttime periods—was consistently evident from Day 7 and maintained through Day 14, whereas famotidine showed a clear time-dependent attenuation of acid-suppressive effect. Safety Tegoprazan was well tolerated in healthy subjects. A total of 3 AEs were reported: 2 events of diarrhea in 2 subjects in the tegoprazan 25 mg QD group and one event of urticaria in one subject in the famotidine 20 mg BID group. All AEs were mild in severity and judged as possibly related to the study drug. No unexpected adverse drug reactions were observed. There were no serious adverse events, study discontinuations, or study drug withdrawals due to AEs during the study period. Furthermore, no clinically significant changes from baseline were observed in physical examinations, clinical laboratory tests, vital signs, or 12-lead ECGs. DISCUSSION In this study, the PKs, PD, and safety profiles of tegoprazan 12.5 mg administered BID, tegoprazan 25 mg QD, and famotidine 20 mg BID were evaluated in healthy subjects following oral administration for 14 days after meals. The 2 tegoprazan regimens showed comparable systemic exposure based on AUC, with the 12.5 mg BID regimen exhibiting higher trough concentrations and peak concentrations that exceeded the expected 0.5 ratio derived from dose reduction. The GMR of steady-state Cmax was approximately 0.7, reflecting this observation. These findings suggest that dosing frequency and accumulation contribute meaningfully to systemic exposure, beyond the linearity of dose alone. However, systemic exposure (AUC) was comparable between groups, with GMRs close to 1.0, indicating similar overall drug exposure upon repeated dosing. From a PD standpoint, famotidine 20 mg BID initially provided rapid acid suppression, but a well-known tachyphylaxis effect reduced its efficacy over time. On Day 1, the degree of gastric acid suppression was comparable to that observed with tegoprazan. However, a progressive loss of PD effect was observed from Day 7 onward, with further attenuation by Day 14, consistent with previous findings. In contrast, tegoprazan 12.5 mg BID maintained stable and sustained efficacy through Day 14, without evidence of tachyphylaxis. These differences were particularly evident in baseline-adjusted outcomes, including mean pH and percentage of time with intragastric pH > 3 or 4, where famotidine showed minimal improvement while both tegoprazan regimens demonstrated clear and persistent effects. This time-dependent attenuation with famotidine was clearly demonstrated by a significant reduction in 24-hour TpH > 3 from 65.3% on Day 1 to 45.1% on Day 7 and further to 40.3% on Day 14. In contrast, both tegoprazan regimens showed no comparable time-dependent attenuation, maintaining relatively stable 24-hour acid control over the same period (12.5 mg BID: from 71.8% to 75.1%; 25 mg QD: from 56.4% to 55.4%). These between-group differences were statistically significant after adjustment for multiple comparisons, underscoring the clinical relevance of sustained acid suppression with tegoprazan. These findings are of clinical relevance, as nighttime gastric acid breakthrough is a common contributor to reflux-related symptoms and sleep disturbance. Importantly, superior acid-suppressive effect of tegoprazan over famotidine was demonstrated from Day 7 and maintained through Day 14 across all postural and temporal conditions. Unlike H2-receptor antagonists, which act on upstream histamine receptors and are prone to receptor-level tolerance with repeated use [1415], tegoprazan acts directly and reversibly on the final effector of acid secretion—the H+/K+-ATPase [1416]. This mechanism minimizes receptor desensitization or upregulation effects and explains the sustained acid-suppressive efficacy observed over 14 days without evidence of tachyphylaxis [1516]. Although no statistically significant differences were observed in the overall 24-hour PD parameters between the 2 tegoprazan regimens, a consistent numerical advantage was observed for the 12.5 mg BID regimen over the 25 mg QD regimen, particularly during the nighttime and supine periods. On Day 14, these differences reached statistical significance across multiple endpoints, highlighting the potential benefit of split dosing even at the lowest approved dose. These results align with prior findings that twice-daily dosing of acid-suppressive therapy may offer enhanced nocturnal acid control [17]. Tegoprazan 12.5 mg BID was well tolerated in this study. No AEs were reported in this group, while 3 mild, drug-related AEs occurred in the other treatment groups and resolved without intervention. In addition, no clinically significant changes were observed in physical examinations, vital signs, laboratory tests, or ECGs. However, the limited sample size and short study duration restrict the generalizability of the safety findings. Furthermore, although famotidine 20 mg BID served as an active control, dose equivalence between this regimen and tegoprazan was not formally established, which may limit direct quantitative comparisons. Although multiplicity correction was applied, the exploratory nature of the study still imposes limitations on statistical inference. Thus, these findings should be interpreted with caution and considered hypothesis-generating. Nonetheless, the consistent and durable acid-suppressive effects observed with tegoprazan 12.5 mg BID—particularly during clinically relevant nocturnal periods—underscore its potential as an effective therapeutic option. Further confirmatory studies in patient populations are warranted to evaluate the clinical utility of split dosing and its role in optimizing the management of acid-related disorders.